Abstract
Ischemic brain injury is implicated in the pathophysiology of stroke and brain trauma, which are among the top killers worldwide, and intensive studies have been performed to reduce neural cell death after cerebral ischemia. Alpha 2- adrenergic agonists have been shown to improve the histomorphological and neurological outcome after cerebral ischemic injury when administered during ischemia, and recent studies have provided considerable evidence that alpha 2-adrenergic agonists can protect the brain from ischemia/reperfusion injury. Thus, alpha 2-adrenergic agonists are promising potential drugs in preventing cerebral ischemic injury, but the mechanisms by which alpha 2-adrenergic agonists exert their neuroprotective effect are unclear. Activation of both the alpha 2-adrenergic receptor and imidazoline receptor may be involved. This mini review examines the recent progress in alpha 2-adrenergic agonists - induced neuroprotection and its proposed mechanisms in cerebral ischemic injury.
Keywords: alpha -adrenergic agonist, adrenoceptor, imidazoline receptor, cerebral ischemia, neuroprotection, excitatory amino acids, sympathoinhibition, stroke
Current Neuropharmacology
Title: Neuroprotection by Alpha 2-Adrenergic Agonists in Cerebral Ischemia
Volume: 3 Issue: 4
Author(s): Y. Zhang and H. K. Kimelberg
Affiliation:
Keywords: alpha -adrenergic agonist, adrenoceptor, imidazoline receptor, cerebral ischemia, neuroprotection, excitatory amino acids, sympathoinhibition, stroke
Abstract: Ischemic brain injury is implicated in the pathophysiology of stroke and brain trauma, which are among the top killers worldwide, and intensive studies have been performed to reduce neural cell death after cerebral ischemia. Alpha 2- adrenergic agonists have been shown to improve the histomorphological and neurological outcome after cerebral ischemic injury when administered during ischemia, and recent studies have provided considerable evidence that alpha 2-adrenergic agonists can protect the brain from ischemia/reperfusion injury. Thus, alpha 2-adrenergic agonists are promising potential drugs in preventing cerebral ischemic injury, but the mechanisms by which alpha 2-adrenergic agonists exert their neuroprotective effect are unclear. Activation of both the alpha 2-adrenergic receptor and imidazoline receptor may be involved. This mini review examines the recent progress in alpha 2-adrenergic agonists - induced neuroprotection and its proposed mechanisms in cerebral ischemic injury.
Export Options
About this article
Cite this article as:
Zhang Y. and Kimelberg K. H., Neuroprotection by Alpha 2-Adrenergic Agonists in Cerebral Ischemia, Current Neuropharmacology 2005; 3 (4) . https://dx.doi.org/10.2174/157015905774322534
DOI https://dx.doi.org/10.2174/157015905774322534 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Cardiac Remodeling and Exercise Training in Hypertension
Current Hypertension Reviews Anti-Inflammatory Therapeutic Approaches to Reduce Acute Atherosclerotic Complications
Current Pharmaceutical Biotechnology Benefits of Caloric Restriction on Brain Aging and Related Pathological States: Understanding Mechanisms to Devise Novel Therapies
Current Medicinal Chemistry The Therapeutic Potential of Neuro-EPO Administered Nasally on Acute Cerebrovascular Disease
Current Psychopharmacology Renin Angiotensin System (RAS) and Immune System Profile in Specific Subgroups with COVID-19
Current Medicinal Chemistry GDF 15 - A Novel Biomarker in the Offing for Heart Failure
Current Cardiology Reviews NAP and ADNF-9 Protect Normal and Downs Syndrome Cortical Neurons from Oxidative Damage and Apoptosis
Current Pharmaceutical Design Anticancer Actions of Omega-3 Fatty Acids - Current State and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Glycation and Hypoxia: Two Key Factors for Adipose Tissue Dysfunction
Current Medicinal Chemistry Gluconic Acid Production
Recent Patents on Biotechnology The Importance of Reendothelialization After Arterial Injury
Current Pharmaceutical Design Advantages and Limitations of Transgenic Mice: The Role of the Na<sup>+</sup>/Ca<sup>2+</sup> Exchanger in Cardiac Electrophysiology and Arrhythmia
Current Medicinal Chemistry Novel Imaging Techniques in Acute Kidney Injury
Current Drug Targets Fetal Origins of Cardiovascular Disease
Current Cardiology Reviews Targeting Leukostasis for the Treatment of Early Diabetic Retinopathy
Cardiovascular & Hematological Disorders-Drug Targets Therapeutic Medical Hypothermia-A Multispecialty Approach
Recent Patents on Cardiovascular Drug Discovery Nitric Oxide is a Central Common Metabolite in Vascular Dysfunction Associated with Diseases of Human Pregnancy
Current Vascular Pharmacology Oxidative and Nitrosative Stress and Immune-inflammatory Pathways in Patients with Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS)
Current Neuropharmacology Induction and Amelioration of Environmental Stress in Isolated Islets Until Transplantation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Mechanisms of Neurodegeration in Type 2 Diabetes and the Neuroprotective Potential of Dipeptidyl Peptidase 4 Inhibitors
Current Medicinal Chemistry